Intravenous enzyme replacement therapy (ERT) with agalsidase alfa (Replagal®, Shire-Takeda, Stockholm, Sweden) or agalsidase beta (Fabrazyme®, Sanofi-Genzyme, Amsterdam, The Netherlands) has been available since 2000 for all patients with Fabry disease [6,7]. Here, GLA is linked to Fabry disease.